Trump said he will raise tariffs on $250 billion in Chinese goods to 30%, and hike duties on another $300 billion in products to 15%.Politicsread more
Stocks dropped after Donald Trump ordered that U.S. manufacturers find alternatives to their operations in China.US Marketsread more
Federal Reserve Vice Chair Richard Clarida said Friday that the global economy has deteriorated in the past month.Marketsread more
The latest escalation in the trade war ups the odds the economy will fall into recession and that the Fed will aggressively cut rates.Market Insiderread more
Here are the products that stand to be the most affected by China's new tariffs on $75 billion worth of U.S. goods.Marketsread more
"We don't need China and, frankly, would be far better off without them," Trump tweeted.Politicsread more
"My only question is, who is our bigger enemy, Jay Powell or Chairman Xi?" Trump wrote amid a series of tweets that rattled markets Friday.Politicsread more
The final week of August could be highly volatile as markets fret over the economy and the latest developments in trade wars.Market Insiderread more
The death comes as federal and state health officials investigate a slew of lung illnesses in connection to e-cigarette use.Health and Scienceread more
Bank of England Governor Mark Carney says trade war has a confidence effect on business around the worldMarketsread more
Supreme Court Justice Ruth Bader Ginsburg has completed a three-week course of radiation therapy for cancer, the top court said in a statement Friday.Politicsread more
Goldman Sachs added Biogen to its Americas Conviction List, highlighting the biotech company's lead pipeline Alzheimer's drug as possibly one of the first to successfully prevent or slow the progression of the disease.
"Biogen has a broad Alzheimer's disease portfolio, which, if successful, would allow it to access a greenfield, blockbuster market opportunity," wrote Goldman analyst Terence Flynn. "It is difficult to overstate the growing societal burden of Alzheimer's disease. … By 2050, one new case of Alzheimer's disease is expected to develop every 33 seconds in the United States."
Cambridge, Massachusetts-based Biogen focuses on discovering and developing therapies for neurological and hematologic disorders including multiple sclerosis and hemophilia. Through a partnership with Eisai, the companies have two Alzheimer's drugs in late-stage development, both of which could be huge money generators.
Goldman projects that sales of one of the drugs, Aducanumab, could reach $12 billion.
The analyst has a $338 price target on Biogen, representing 17 percent upside from Tuesday's close. The shares rose 2.5 percent Wednesday morning after Goldman's call.
Biogen is also a key player in treatment of multiple sclerosis, handling 38 percent of all MS patients globally. With more and more competitors entering the MS market, Biogen has started to feel pressure on some of its established drugs.
"MS is a mature market and competition has been increasing. But while generics and other new entrants could capture share, we don't expect wholesale 're-pricing' of the category," Flynn said.
In all, Goldman Sachs not only sees room for drug catalysts, but additional business development could provide Biogen with free cash.
"Our firepower analysis suggests $14 billion in capacity, which is above what management discussed on the 2Q call regarding the maximum size deal it could pursue," Flynn wrote.
"Hence, in addition to potential business development deals, we believe the company could more aggressively repurchase shares."